المؤلفون: YUMUK, PERRAN FULDEN

المساهمون: Kilickap, S., Demirci, U., Bugdayci, F., Tural, D., Korkmaz, T., Paydas, S., Yilmaz, C., Turna, H., Sezer, A., Cinkir, H. Yesil, Okutur, K., Erman, M., Eralp, Y., Cabuk, D., Isikdogan, A., Demirkazik, A., Karaoglu, A., Yazilitas, D., Senler, F. Cay, Yumuk, P. F., Coskun, H., Yildiz, I., Oztop, I., Beypinar, I., Aydin, K., Kaplan, M., Meydan, N., Olmez, O. F., Ozyilkan, O., Seber, S., Arslan, C., Sendur, M. A., Cicin, I.

مصطلحات موضوعية: ALK positive, ROS1 positive, Lorlatinib, Advanced stage lung cancer

وصف الملف: application/pdf

Relation: JOURNAL OF THORACIC ONCOLOGY; https://hdl.handle.net/11424/246077; WOS:000492162203082

الاتاحة: https://hdl.handle.net/11424/246077
https://doi.org/10.1016/j.jtho.2019.08.1166

المؤلفون: Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll, Romana Wass, Elmar Brehm, Gudrun Absenger, Tatjana Bundalo, Peter Errhalt, Matthias Urban, Arschang Valipour

المصدر: Pharmaceuticals; Volume 13; Issue 11; Pages: 371

مصطلحات موضوعية: ALK -positive disease, ROS1 -positive disease, ALK tyrosine kinase inhibitor treatment, sequential treatment, lorlatinib

وصف الملف: application/pdf

Relation: Pharmacology; https://dx.doi.org/10.3390/ph13110371

الاتاحة: https://doi.org/10.3390/ph13110371

المؤلفون: Kılıçkap, Saadettin, Demirci, Umut, Buğdaycı, Fatma, Tural, Deniz, Korkmaz, Taner, Paydaş, Semra, Yılmaz, Coşkun, Tuna, Hande, Sezer, Ahmet, Yeşil Çinkir, Havva, Erman, Münire, Eralp, Yeşim, Çabuk, Devrim, Işıkdoğan, Abdurrahman, Demirkazık, Ahmet, Karaoğlu, Aziz, Yazılıtaş, Doğan, Çay Şenler, Filiz, Yumuk, Perran Fulden, Coşkun, Hatice, Yıldız, İbrahim, Öztop, İlhan, Beypınar, İsmail, Aydın, Kübra, Kaplan, M., Meydan, Nezih, Ölmez, Ömer Fatih, Seber, Samile, Arslan, Çağatay, Şendur, Mehmet Ali Nahit, Çiçin, İrfan

مصطلحات موضوعية: Lorlatinib, ALK Positive, hemic and lymphatic diseases, Advanced Stage Lung Cancer, ROS1 Positive

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______9477::f3b862dc4ea4cbbc2f40d39ada2d7c2a
https://hdl.handle.net/20.500.12511/4670

المؤلفون: Nikhil Pande, Anuradha Chougule, Vanita Noronha, Trivedi Vaishakhi, Amit Joshi, Abhishek Mahajan, Vijay Patil, Kumar Prabhash, Rajesh Kumar, Amit Janu

المصدر: ecancermedicalscience

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, ROS1 positive, adenocarcinoma lung, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, ROS1, Anaplastic lymphoma kinase, Lung cancer, crizotinib, Performance status, Crizotinib, business.industry, Research, Cancer, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, Cohort, Adenocarcinoma, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5c552249f917876bacf6bc0b843d1e9
http://europepmc.org/articles/PMC6390829